150 related articles for article (PubMed ID: 1546335)
1. Growth plate injury of the long bones in treated beta-thalassemia.
Orzincolo C; Scutellari PN; Castaldi G
Skeletal Radiol; 1992; 21(1):39-44. PubMed ID: 1546335
[TBL] [Abstract][Full Text] [Related]
2. [Rickets- and/or scurvy-like bone lesions in beta-thalassemia major].
Orzincolo C; Castaldi G; De Sanctis V; Scutellari PN; Ciaccio C; Vullo C
Radiol Med; 1990 Dec; 80(6):823-9. PubMed ID: 2281161
[TBL] [Abstract][Full Text] [Related]
3. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
4. Deferoxamine-induced growth retardation in patients with thalassemia major.
De Virgiliis S; Congia M; Frau F; Argiolu F; Diana G; Cucca F; Varsi A; Sanna G; Podda G; Fodde M
J Pediatr; 1988 Oct; 113(4):661-9. PubMed ID: 3171791
[TBL] [Abstract][Full Text] [Related]
5. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Giardina PJ; Grady RW
Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
[TBL] [Abstract][Full Text] [Related]
6. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine.
De Sanctis V; Pinamonti A; Di Palma A; Sprocati M; Atti G; Gamberini MR; Vullo C
Eur J Pediatr; 1996 May; 155(5):368-72. PubMed ID: 8741032
[TBL] [Abstract][Full Text] [Related]
7. Desferrioxamine and urinary zinc excretion in beta-thalassemia major.
Uysal Z; Akar N; Kemahli S; Dincer N; Arcasoy A
Pediatr Hematol Oncol; 1993; 10(3):257-60. PubMed ID: 8217542
[TBL] [Abstract][Full Text] [Related]
8. Iron chelating therapy in thalassemia: current problems.
Russo G
Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
[No Abstract] [Full Text] [Related]
9. [The evolutionary effects of therapy on the skeletal lesions in beta-thalassemia].
Orzincolo C; Castaldi G; Bariani L; Scutellari PN
Radiol Med; 1994 Apr; 87(4):381-8. PubMed ID: 8190918
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
11. The management of haemoglobinopathies.
Davies SC; Wonke B
Baillieres Clin Haematol; 1991 Apr; 4(2):361-89. PubMed ID: 1912665
[No Abstract] [Full Text] [Related]
12. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
[TBL] [Abstract][Full Text] [Related]
13. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
14. Current status of iron chelation therapy with deferoxamine.
Cohen A
Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
Ehlers KH; Giardina PJ; Lesser ML; Engle MA; Hilgartner MW
J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928
[TBL] [Abstract][Full Text] [Related]
16. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
[TBL] [Abstract][Full Text] [Related]
17. MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.
Miller TT; Caldwell G; Kaye JJ; Arkin S; Burke S; Brill PW
Pediatr Radiol; 1993; 23(7):523-4. PubMed ID: 8309753
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of skeletal dysplasia in thalassaemia major.
Naselli A; Vignolo M; Di Battista E; Garzia P; Forni GL; Traverso T; Aicardi G
J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():817-25. PubMed ID: 10091152
[TBL] [Abstract][Full Text] [Related]
19. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
Athanassiou-Metaxa M; Kousi A; Hatzipantelis ES; Tsatra I; Ikonomou M; Perifanis V; Tsantali H
Haematologica; 2004 Apr; 89(4):ELT07. PubMed ID: 15075120
[No Abstract] [Full Text] [Related]
20. Oral iron chelation therapy for thalassaemia: an uncertain scene.
Pippard MJ; Weatherall DJ
Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
[No Abstract] [Full Text] [Related]
[Next] [New Search]
